Cargando…
The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study
BACKGROUND: Management of nontuberculous mycobacterial lung disease (NTMLD) consists of a long-term multi-drug antibiotic regimen, yet many patients do not achieve culture conversion. We estimated the NTMLD-related direct medical costs in Canada, France, Germany, and the United Kingdom (UK) among re...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131733/ https://www.ncbi.nlm.nih.gov/pubmed/30200944 http://dx.doi.org/10.1186/s12913-018-3489-8 |
_version_ | 1783354179986653184 |
---|---|
author | Goring, S. M. Wilson, J. B. Risebrough, N. R. Gallagher, J. Carroll, S. Heap, K. J. Obradovic, M. Loebinger, M. R. Diel, R. |
author_facet | Goring, S. M. Wilson, J. B. Risebrough, N. R. Gallagher, J. Carroll, S. Heap, K. J. Obradovic, M. Loebinger, M. R. Diel, R. |
author_sort | Goring, S. M. |
collection | PubMed |
description | BACKGROUND: Management of nontuberculous mycobacterial lung disease (NTMLD) consists of a long-term multi-drug antibiotic regimen, yet many patients do not achieve culture conversion. We estimated the NTMLD-related direct medical costs in Canada, France, Germany, and the United Kingdom (UK) among refractory patients who were infected with Mycobacterium avium complex (MAC), without concomitant cystic fibrosis, tuberculosis, or HIV. METHODS: We conducted a retrospective observational physician survey of nationally representative samples. The survey captured anonymized information about patients’ treatment histories for NTMLD-related health care resource utilization over a 24-month period. We summarized NTMLD-related resource use and estimated the total economic burden, from each country’s health care payer perspective. RESULTS: In total, 59 physicians provided data on 157 patients. The average person time observed during the 24-month period was 1.7 years (SD: 0.4); 17% of patients died by the end of the study period. The major components of NTMLD-related direct medical costs among refractory patients were hospitalizations (varying from 29% of total annual costs in the UK to 69% in France), outpatient visits (8% in Canada to 51% in the UK), and outpatient testing such as post-diagnostic sputum testing, bronchial wash/lavage, spirometry, biopsies, imaging, and electrocardiograms (5% in France to 35% in Canada). In this patient cohort, the average direct medical costs per person-year, in local currencies, were approximately $16,200 (Canada), €11,600 (Germany), €17,900 (France) and £9,700 (UK). CONCLUSIONS: Based on this study’s findings, we conclude that managing patients with refractory NTMLD caused by MAC is associated with a substantial economic burden. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12913-018-3489-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6131733 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-61317332018-09-13 The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study Goring, S. M. Wilson, J. B. Risebrough, N. R. Gallagher, J. Carroll, S. Heap, K. J. Obradovic, M. Loebinger, M. R. Diel, R. BMC Health Serv Res Research Article BACKGROUND: Management of nontuberculous mycobacterial lung disease (NTMLD) consists of a long-term multi-drug antibiotic regimen, yet many patients do not achieve culture conversion. We estimated the NTMLD-related direct medical costs in Canada, France, Germany, and the United Kingdom (UK) among refractory patients who were infected with Mycobacterium avium complex (MAC), without concomitant cystic fibrosis, tuberculosis, or HIV. METHODS: We conducted a retrospective observational physician survey of nationally representative samples. The survey captured anonymized information about patients’ treatment histories for NTMLD-related health care resource utilization over a 24-month period. We summarized NTMLD-related resource use and estimated the total economic burden, from each country’s health care payer perspective. RESULTS: In total, 59 physicians provided data on 157 patients. The average person time observed during the 24-month period was 1.7 years (SD: 0.4); 17% of patients died by the end of the study period. The major components of NTMLD-related direct medical costs among refractory patients were hospitalizations (varying from 29% of total annual costs in the UK to 69% in France), outpatient visits (8% in Canada to 51% in the UK), and outpatient testing such as post-diagnostic sputum testing, bronchial wash/lavage, spirometry, biopsies, imaging, and electrocardiograms (5% in France to 35% in Canada). In this patient cohort, the average direct medical costs per person-year, in local currencies, were approximately $16,200 (Canada), €11,600 (Germany), €17,900 (France) and £9,700 (UK). CONCLUSIONS: Based on this study’s findings, we conclude that managing patients with refractory NTMLD caused by MAC is associated with a substantial economic burden. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12913-018-3489-8) contains supplementary material, which is available to authorized users. BioMed Central 2018-09-10 /pmc/articles/PMC6131733/ /pubmed/30200944 http://dx.doi.org/10.1186/s12913-018-3489-8 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Goring, S. M. Wilson, J. B. Risebrough, N. R. Gallagher, J. Carroll, S. Heap, K. J. Obradovic, M. Loebinger, M. R. Diel, R. The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study |
title | The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study |
title_full | The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study |
title_fullStr | The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study |
title_full_unstemmed | The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study |
title_short | The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study |
title_sort | cost of mycobacterium avium complex lung disease in canada, france, germany, and the united kingdom: a nationally representative observational study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6131733/ https://www.ncbi.nlm.nih.gov/pubmed/30200944 http://dx.doi.org/10.1186/s12913-018-3489-8 |
work_keys_str_mv | AT goringsm thecostofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT wilsonjb thecostofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT risebroughnr thecostofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT gallagherj thecostofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT carrolls thecostofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT heapkj thecostofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT obradovicm thecostofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT loebingermr thecostofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT dielr thecostofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT goringsm costofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT wilsonjb costofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT risebroughnr costofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT gallagherj costofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT carrolls costofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT heapkj costofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT obradovicm costofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT loebingermr costofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy AT dielr costofmycobacteriumaviumcomplexlungdiseaseincanadafrancegermanyandtheunitedkingdomanationallyrepresentativeobservationalstudy |